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Summary
Background: In response to varied cell stress signals,
the p53 tumor-suppressor protein activates a multitude
of genes encoding proteins with functions in cell-cycle
control, DNA repair, senescence, and apoptosis. The
role of p53 in transcription of other types of RNAs, such
as microRNAs (miRNAs) is essentially unknown.
Results: Using gene-expression analyses, reporter
gene assays, and chromatin-immunoprecipitation ap-
proaches, we present definitive evidence that the abun-
dance of the three-member miRNA34 family is directly
regulated by p53 in cell lines and tissues. Using array-
based approaches and algorithm predictions, we define
genes likely to be directly regulated by miRNA34, with
cell-cycle regulatory genes being the most prominent
class. In addition, we provide functional evidence, ob-
tained via antisense oligonucleotide transfection and
the use of mouse embryonic stem cells with loss of
miRNA34a function, that the BCL2 protein is regulated
directly by miRNA34. Finally, we demonstrate that the
expression of two miRNA34s is dramatically reduced
in 6 of 14 (43%) non-small cell lung cancers (NSCLCs)
and that the restoration of miRNA34 expression inhibits
growth of NSCLC cells.
Conclusions: Taken together, the data suggest the
miRNA34s might be key effectors of p53 tumor-
suppressor function, and their inactivation might con-
tribute to certain cancers.
Introduction
In large part because somatic mutations inactivating
p53 function are present in more than 50% of all human
cancers, the p53 tumor-suppressor gene and its protein
product have been intensely studied for two decades.
*Correspondence: fearon@umich.eduThe p53 protein is a sequence-specific transcription
factor. Various cellular stresses, such as DNA damage,
hypoxia, and nutrient deprivation, can activate p53 func-
tion via effects on p53 stability and nuclear localization
and its interactions with other proteins, resulting ulti-
mately in p53-stimulated transcription of perhaps a
hundred or more genes [1]. The p53-regulated genes
encode proteins sharing functions in regulation of cell-
cycle progression, DNA repair, apoptosis, and angio-
genesis, and in feedback regulation of p53 function [2].
In aggregate, studies of upstream activators and down-
stream mediators of p53 function have greatly informed
knowledge of why the p53 gene is commonly inactivated
by somatic mutations of its own coding sequences or by
defects in key proteins that regulate p53, such as MDM2
gain-of-function or p14ARF loss-of-function mutations
[2]. Nonetheless, although enormous attention has been
focused on mRNAs regulated by p53, to date, little is
known about p53’s role in the transcription of other
types of RNA, such as microRNAs (miRNAs).
miRNAs are short, noncoding RNAs of 18 to 24 nucle-
otides length. Longer precursor transcripts with hairpin
structures are first synthesized by RNA polymerase II,
and, after processing of the precursors by Drosha and
Dicer ribonucleases, mature miRNAs are generated (re-
viewed in [3]). Depending on the degree of homology
to their target sequence, miRNAs induce translational
repression or cleavage of mRNAs. A single miRNA can
target hundreds to a thousand or more mRNAs [4], ren-
dering it challenging to attribute distinct functions to
specific miRNAs. Perhaps as a result of this complexity,
in spite of the evolutionary conservation of miRNAs,
their function in physiology and disease remains rather
enigmatic.
Notwithstanding the challenges, insights into the po-
tential contributing roles of miRNAs in cancer have been
obtained. Comprehensive analyses of miRNA expres-
sion patterns in human cancers have been reported, and
the findings suggest that different cancer types have
distinct miRNA expression patterns [5–7]. Other studies
of miRNAs in cancer have also pointed to the function
of certain miRNAs as oncogenes. For instance, the
miRNA17-92 polycistron at chromosome 13q31.3 en-
codes seven miRNAs, and the polycistron has been re-
ported to be genomically amplified and overexpressed
in some human B cell lymphomas and lung cancers
[8]. Transcription of the miRNA17-92 polycistron is reg-
ulated by c-MYC and E2F proteins, and this polycis-
tronic transcript cooperated with c-MYC to accelerate
lymphoma development in a murine-model system [8,
9]. In addition, miRNA155, has been reported to be over-
expressed in several lymphoma subtypes [10, 11]. With
respect to potential tumor-suppressor activities for
miRNAs, decreased levels of miRNA143 and miRNA145
were seen in colorectal cancer [12], and decreased
levels of miRNA15 and miRNA16 have been described
in chronic lymphocytic leukemia [5, 13–15]. In addition,
the members of the let-7 family of miRNAs have been
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posedly in part by their ability to target the K-Ras and
HMGA2 oncogenes [16–18]. Notably, inhibition of global
miRNA processing has recently been shown to lead to
increased tumorigenicity and transformation, suggest-
ing that the decreased expression of multiple miRNAs
might be important in tumorigenesis [19].
Results
Direct Regulation of miRNA34 Family
Members by p53
The miRNA34 family comprises three members:
miRNA34a, which is generated from a larger transcrip-
tional unit on chromosome 1p36, and miRNA34b and
miRNA34c, both of which are generated by processing
of a bicistronic transcript from chromosome 11q23
(termed miRNA34bc). Based on our analysis of the re-
sults of a published genome-wide chromatin immuno-
precipitation (ChIP) study from Wei et al. [20], we noted
a presumptive p53 binding region within 30 kb of the
precursor transcription units for both miRNA34a and
miRNA34bc. Although putative p53 binding sites exist
in the vicinity of numerous other precursor transcripts
for miRNAs, the coincidence of binding sites in proximity
to both the miRNA34a and miRNA34bc precursors
spurred our interest.
The transcriptional activity of p53 can be readily in-
duced in cells by exposure to genotoxic stress, such
as the chemotherapeutic agent adriamycin. Treatment
of the Wi38 human diploid fibroblast cell line with adria-
mycin led to a potent activation of miRNA34a (Figure 1A).
This increase was nearly completely inhibited in Wi38
cells stably expressing a short hairpin RNA (shRNA)
targeting p53 [21]. A marked increase in miRNA34a
levels was also seen in spleen tissue obtained 12 hr after
whole-body irradiation of wild-type mice (Figure 1B),
and the induction of miRNA34a was lacking in spleen tis-
sue from irradiated p532/2 mice. Based on our analysis
of cDNA sequences in the database, the chromosome
1p36 precursor transcript for miRNA34a is predicted to
be spliced, with the candidate p53 DNA binding site
located upstream of the transcriptional start site in a
well-conserved DNA sequence region present within a
CpG island (Figure 1C). A luciferase-based reporter gene
construct containing key sequences from the locus was
generated by subcloning an 837 bp genomic fragment
containing the presumptive transcriptional start site and
the candidate p53 binding site. Cotransfection of the re-
porter construct with a wild-type p53 cDNA expression
vector potently activated the reporter gene, whereas a
p53 cDNA carrying a missense mutation [22] or a control
(empty) expression vector were inactive (Figure 1D, left).
The mutation of key nucleotides in the presumptive p53
binding site abolished activation of the reporter gene by
wild-type p53 (Figure 1D, right). ChIP with a p53 anti-
body demonstrated that DNA sequences containing the
presumptive p53 binding site could be specifically re-
covered from HCT116 cells expressing wild-type p53,
after treatment of cells with 5-fluorouracil (5-FU) to acti-
vate p53, but not from an isogenic cell line in which p53
had been inactivated by homologous recombination
(Figure 1E) [23].Studies analogous to those for miRNA34a were then
undertaken for miRNA34b and the miRNA34bc precur-
sor transcriptional unit on chromosome 11q23. Adria-
mycin treatment of Wi38 cells led to markedly increased
levels of miRNA34b, and shRNA-mediated inhibition of
p53 function abrogated the induction of miRNA34b by
adriamycin (Figure 2A). Irradiation of wild-type mice,
but not p532/2 mice, led to markedly increased levels
of miRNA34b in the spleen (Figure 2B). Examination of
the 11q23 locus for the miRNA34bc precursor transcrip-
tional unit revealed a candidate p53 DNA binding site
upstream of the transcriptional start site (Figure 2C). A
reporter gene construct containing a 555 bp fragment
that includes the p53 binding site and the predicted tran-
scriptional start site was strongly activated by cotrans-
fection of a wild-type p53 cDNA, but not by a p53 cDNA
with a missense mutation or control expression vector
(Figure 2D, left). Mutations in the candidate p53 binding
site abrogated the ability of wild-type p53 to induce
reporter gene activation (Figure 2D, right).
Identification of miRNA34-Regulated Genes
As noted above, depending on the cellular context, the
p53 protein can regulate cell-cycle progression and
apoptosis induction. In light of the evidence that p53
acts directly to increase miRNA34 levels, we assessed
whether ectopic miRNA34 expression had effects simi-
lar to those of p53. We used the p53 mutant colon cancer
cell line SW480 as a model because these cells have
only low levels of expression for the three miRNA34 fam-
ily members. We created a polyclonal SW480 line that, in
response to doxycyclin (dox) treatment, expressed a
longer precursor transcript that is cleaved to generate
mature miRNA34a (SW480 miRNA34), along with green
fluorescent protein (GFP). We also generated a control
polyclonal SW480 cell line that expressed only GFP in
response to dox treatment (SW480GFP). As an initial
unbiased approach to assess miRNA34 effects, we ana-
lyzed mRNA transcript profiles in the cells after 3 days
of dox treatment. We fit a two-way analysis of variance
(ANOVA) model to the data, modeling cell type (i.e.,
SW480 miRNA34 or SW480GFP), treatment (i.e., dox
treated or not), as well as interaction between cell type
and treatment. We required a p value of < 0.01 for the
interaction and that the n-fold change upon exposure
to dox be at least 1.5-fold greater in SW480 miRNA34a
cells than in SW480GFP cells. This analysis highlighted
1012 probe sets (corresponding to 766 genes) that
decreased significantly more after dox treatment in the
SW480 miRNA34 line, when compared to the SW480GFP
line (subsequently termed downregulated genes). This
list of potential miRNA34 targets was then compared
with the list of target genes predicted by Targetscan
and Pictar [4, 24–26]. A highly significant enrichment of
predicted miRNA34 targets was observed for the down-
regulated gene list: Among the 313 genes predicted by
Targetscan [4] that were on the arrays, we found 61 in the
downregulated gene group (p = 6.53 10226, Figure S1 in
the Supplemental Data available online). Similar lists of
predicted targets for miRNA34a and miRNA34bc from
Pictar [25, 26] also gave significant enrichments for our
downregulated genes (p = 5.13 10227 and 1.243 10217
respectively). In addition to the role of miRNA binding to
the 30 untranslated region (UTR) of target genes, which is
Current Biology
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(A) WI38 human diploid fibroblast cell lines expressing a shRNA targeting p53 and a scrambled control shRNA were treated with 200 nM Adria-
mycin for 24 hr. Shown are miRNA34a expression levels, as determined by Taqman-based real-time reverse-transcription polymerase chain
reaction (RT-PCR) relative to the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression. Means and standard
deviations are shown.
(B) miRNA34a expression levels in the spleens of p53+/+ (n = 4) and p532/2 (n = 3) mice 12 hr after irradiation with 8Gy. The mean and standard
deviation of expression levels relative to levels of 18S rRNA levels are shown.
(C) Schematic representation of the genomic locus of miRNA34a with an expansion of a conserved predicted p53 binding site. Mutated residues
are marked with an asterisk. DB286351 represents the location of an expressed sequence tag (EST) spanning miRNA34a and the putative p53
binding site.
(D) miRNA34a promoter reporter assay. SW480 cells were transfected with an expression construct for wild-type p53, mutant p53, or empty
vector. Activity of a reporter construct carrying an 837 bp genomic fragment encompassing the putative transcriptional start site of miRNA34a
upstream of a firefly luciferase open reading frame was normalized to the activity of a cotransfected CMV-b-galactosidase construct. Note that
the apparent residual activation of the mutated reporter by wild-type p53 is caused by a concomitant downregulation of the CMV-b-galactosi-
dase normalization vector.
(E) ChIP of a miRNA34a promoter region. Chromatin from HCT116 p53+/+ and HCT116 p532/2 cells was precipitated with a p53 antibody after
treatment with 5-FU for 20 hr. Quantitative PCR of a region flanking the putative p53 binding site in the miRNA34a promoter was used to quantify
the amount of chromatin obtained by immunoprecipitation relative to the amount in the input samples (in percent of input). When analyzing
chromatin that had been immunoprecipitated from HCT116 p53+/+ cells with a p53 antibody, amplification of miRNA34a promoter elements
was observed at cycle 36 or 39 in the presence or absence of 5-FU, respectively. At 42 cycles, no amplification was observed with primers
for a genomic region that is not bound by p53 (data not shown), and no amplification of miRNA34a promoter elements was observed from
the chromatin that had been immunoprecipitated from p532/2 cells. Error bars represent standard deviations.the basis for most target-site-prediction algorithms,
Miranda et al. have recently suggested that binding sites
within the coding sequence of genes might be importantfor miRNA function [27]. We therefore evaluated the cod-
ing sequences of the downregulated genes in compari-
son to the upregulated genes for putative miRNA34a
miRNA34 Family Regulation by p53
1301Figure 2. miRNA34b Is a Direct Transcriptional Target of p53
(A) WI38 human diploid fibroblast cell lines expressing an shRNA targeting p53 and a scrambled control shRNA were treated with 200 nM Adria-
mycin for 24 hr. miRNA34b expression levels as determined by Taqman-based real-time RT-PCR are shown relative to the level of GAPDH mRNA
expression. Means and standard deviations are shown.
(B) miRNA34b expression levels in the spleens of p53+/+ (n = 4) and p532/2 (n = 3) mice 12 hr after irradiation with 8Gy. The mean and standard
deviation of expression levels relative to levels of 18S rRNA levels are shown.
(C) Schematic representation of the genomic locus of miRNA34bc with an expansion of a conserved predicted p53 binding site. Mutated resi-
dues are marked with an asterisk. BC021736 represents the location of an EST spanning miRNA34bc and the putative p53 binding site.
(D) miRNA34bc promoter reporter assay. SW480 cells were transfected with an expression construct for wild-type p53, mutant p53, or empty
vector. Activity of a reporter construct carrying a 555 bp genomic fragment encompassing the putative transcriptional start site of miRNA34bc
upstream of a firefly luciferase open reading frame was normalized to the activity of a cotransfected thymidine-kinase promoter renilla luciferase
construct. Note that the apparent residual activation of the mutated reporter by wild-type p53 reflects concomitant inhibition of the TK-Renilla
normalization vector. Error bars represent standard deviations.binding sites with their RNA22 algorithm [27]. Notably,
we observed a larger fraction of genes with predicted
target sites in the downregulated gene group compared
to the upregulated gene group (31.3% versus 22.7%,p = 0.004), suggesting that miRNA34 also exerts effects
via the targeting of coding-region sequences.
Testing Gene Ontology (GO) terms and the Kyoto En-
cyclopedia of Genes and Genomes (KEGG) pathways,
Current Biology
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Leads to G1 Cell-Cycle Arrest and Downregu-
lation of BCLl2
(A) Cell-cycle distribution of SW480
miRNA34a cells after 3 days treatment with
doxycyclin. Cells were stained with propi-
dium iodide after ethanol fixation. The left
panel shows primary flow cytometry histo-
grams, and the right panel shows quantifica-
tion of populations in different cell-cycle
phases with Modfit3.0. Asterisks mark signif-
icant changes with t test, p < 0.05, and error
bars represent standard deviations.
(B) Cyclin-E2, CDK6, and E2F5 protein levels
are downregulated after induction of
miRNA34a expression. Western-blot analysis
was performed after 3 days of doxycyclin
treatment of SW480 miRNA34a and
SW480GFP cells.
(C) BCL2 protein levels are downregulated
after induction of miRNA34a expression for
3 and 4 days. No inhibition is observed in
control cell lines SW480 GFP. Levels of actin
are shown to demonstrate equal loading
in panels (B) and (C).we found a strong enrichment of ‘‘cell cycle’’ genes in
the list of genes downregulated by miRNA34 ectopic
expression (p = 1.843 1026 and p = 1.343 1026, respec-
tively; see Tables S1 and S2 for the top 20 categories).
This group of genes encoded G1/S regulators, such as
the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6),
Cyclin E2, and the E2F3 and E2F5 transcription factors,
as well as the S phase and M phase regulators Cyclin
A2, CDC25a, and Aurora kinase B (Tables S1 and S2).
While our studies were in progress, data implicating
miRNA34a in translational suppression of E2F3 were
reported [28].
miRNA-Mediated Effects on Cell-Cycle
and Apoptosis Regulation
After miRNA34 induction in SW480 cells, we observed
a G1 arrest, suggesting that miRNA34, similar to p53
itself, regulates cell-cycle progression (Figure 3A). We
confirmed that the expression of several cell-cycle reg-
ulators predicted to be regulated by miRNA34—Cyclin
E2, CDK6, and E2F5—was in fact reduced upon ectopic
expression of miRNA34a (Figure 3B). No changes in mu-
tant p53 protein levels were observed upon miRNA34a
expression (data not shown). We nevertheless were in-
terested to see whether cell-cycle arrest by miRNA34a
had effects on mRNAs and proteins known to be directly
activated by p53. Only very modest changes of p21 pro-
tein levels and BBC3/Puma mRNA levels were observed
(Figure S2). Our list of genes whose expression was
altered upon miRNA34a induction did not show enrich-
ment for genes with known p53 binding sites in their
regulatory region (Figure S2C). This suggests that
miRNA34a induces cell-cycle arrest in a complementary
and parallel fashion to mRNAs that are directly activated
by p53.
Though the list of genes downregulated by miRNA34
was not generally enriched for genes encoding factorswith established roles in apoptosis, we noted that tran-
script levels for the well-known antiapoptotic factor
BCL2 were downregulated by miRNA34 ectopic expres-
sion. Western-blot studies confirmed strong downregu-
lation of BCL2 protein levels by miRNA34 in SW480 cells
(Figure 3C). To establish the role of miRNA34 binding
sites in BCL2 transcripts as a key mechanism contribut-
ing to miRNA34’s effects (Figure 4A), we placed part of
the 30 UTR of BCL2 downstream of luciferase sequences
in an expression construct. Ectopic expression of
miRNA34a significantly reduced the activity of a con-
struct containing the wild-type BCL2 30 UTR, whereas
miRNA34a had no effect on a control construct with two
point mutations in the seed region for miRNA34 binding
(Figure 4B). Because SW480 has very low endogenous
levels of miRNA34s, we assessed the consequences of
antagonizing miRNA34 in Wi38 human embryonic fibro-
blasts, which express all three miRNA34 isoforms at
baseline and show their accumulation upon genotoxic
stress (data not shown). To inhibit all three miRNA34
members, we cotransfected Wi38 cells with antisense
locked nucleic acid (LNA) oligonucleotides (miRNA34as)
targeting all three isoforms. Inhibition of miRNA34 in
Wi38 cells led to an increase in BCL2 levels within 36
hr (Figure 4C). Notably, when Wi38 cells transduced
with miRNA34as were treated with the apoptosis-induc-
ing agent staurosporine for 8 hr, fewer early apoptotic
cells and more viable cells were observed (Figure 4D).
Taken together, the data indicate that miRNA34 can me-
diate key effects associated with p53 function, namely
the inhibition of cell-cycle progression and induction of
apoptosis.
To further characterize the endogenous function of
miRNA34, we generated embryonic stem (ES) cell lines
in which both alleles of miRNA34a had been targeted
for inactivation. Based on quantitative gene-expression
analyses, miRNA34a levels were reduced to background
miRNA34 Family Regulation by p53
1303Figure 4. BCL2 Is a Direct Target of miRNA34
(A) Comparison of a putative miRNA34 bind-
ing site in the 30 UTR of BCL2 in different
species.
(B) miRNA34a inhibits a luciferase reporter
construct carrying the BCL2 30 UTR. Intro-
duction of point mutations in the miRNA bind-
ing site abolishes this regulation. SW480 cells
were transiently transfected with the indi-
cated constructs, and luciferase activity was
normalized to a cotransfected thymidine-
kinase promoter renilla luciferase construct.
(C) Inhibition of miRNA34a,b,c by transfec-
tion of LNA oligonucleotides leads to the up-
regulation of BCL2. LNA antisense oligonu-
cleotides were transfected into Wi38 human
diploid fibroblast cells. Western-blot analysis
for BCL2 and b-actin was performed 36 hr
later.
(D) Inhibition of miRNA34a,b,c protects cells
from apoptosis induced by staurosporine.
Wi38 cells were transfected with antisense
LNA oligonucleotides. After 36 hr, cells were
treated with 1 mM staurosporine for 8 hr. Via-
ble cells refers to cells that do not take up
propidium iodide and do not stain for annexin
V. The average and standard deviation of
viable cells of triplicates are shown.
(E) miRNA34a2/2 ES cells show increased
levels of BCL2 upon induction of differentia-
tion. Two clones with disruption of one allele
of the miRNA34a gene (B4 and D2) and two
clones with disruption of both miRNA34a
alleles (2C4 and 2D6) were assessed for BCL2
expression levels 3 days after induction of
differentiation by 1 mM retinoic acid and with-
drawal of LIF. The expression of b-actin is
shown as loading control.
(F) miRNA34a2/2 ES cells show reduced levels of baseline apoptosis after induction of differentiation (as in [E]). The average and standard
deviation of the percentage of early apoptotic cells (staining with annexin V, no propidium iodide uptake), total annexin V-stained cells, and total
propidium-iodide-uptaking cells in miRNA34a+/2 and miRNA34a2/2 cell lines are shown.levels when two independent homozygous knockout
clones were compared to two heterozygous clones
(Figure S3). Although no change in basal apoptosis fre-
quency or cell-cycle parameters were observed in undif-
ferentiated ES cells, we observed significantly higher
BCL2 protein levels three days after induction of differ-
entiation by the withdrawal of leukemia inhibitory factor
(LIF) and treatment with retinoic acid (Figure 4E), con-
firming a role of endogenous miRNA34a in regulating
BCL2 protein levels. In addition, basal levels of apopto-
sis were reduced in the differentiated miRNA34a homo-
zygous knockout cells (Figure 4F). It has previously been
shown that BCL2 is only expressed at low levels in undif-
ferentiated ES cells and that transcript levels increase
during differentiation [29]. This might explain why the
effect on baseline apoptosis was only apparent upon
the induction of differentiation. The fact that the loss of
miRNA34a expression induces a phenotype despite
intact miRNA34bc function might be explained by the
overall lower miRNA34b and miRNA34c levels in the
cell lines (Figure S4).
Differential Expression of miRNA34-Family-Member
Expression in Normal Tissues and Silencing
of miRNA34bc in a Subset of Lung Cancers
The miRNA34 family is highly conserved through evolu-
tion (Figure 5A). In contrast to Drosophila or C. elegans,vertebrates have three miRNA34 family members, which
are generated from two distinct genomic loci. The nucle-
otide sequences of the three miRNA34 isoforms are
highly similar. Based on present knowledge of transcript
recognition by miRNAs, each miRNA34 isoform is pre-
dicted to target almost the same transcripts. Hence,
although it is possible that the apparent redundancy
reflects a potential fail-safe system, the basis for three
miRNA34 isoforms might reflect tissue-specific differ-
ences in expression. We found that miRNA34a was pres-
ent at highest levels in the brain, with variable expression,
ranging from low to moderate, in other tissues assayed
(Figure 5B). miRNA34b was most highly expressed in
lung, with low expression in brain and very low to unde-
tectable expression in other tissues studied (Figure 5C).
Expression of miRNA34c in normal mouse tissues strictly
paralleled miRNA34b expression (Figure S5).
To explore the possibility that miRNA34 isoforms
might be downregulated in cancer tissues, we focused
attention on miRNA34bc and non-small cell lung can-
cers (NSCLCs) because miRNA34bc was present at
highest levels in normal lung tissue. We found that
miRNA34b levels were decreased by more than 90% in
six out of the 14 NSCLCs, including four of five adeno-
carcinomas, two of eight squamous cell carcinomas,
and zero of one large cell carcinomas (Figure 5E). Three
of 14 NSCLCs had aw2-fold upregulation of miRNA34b
Current Biology
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miRNA34 Gene Family and miRNA34bc
Downregulation in a Subset of Non-Small
Cell Lung Cancers
(A) Conservation of mature miRNA34 se-
quences throughout evolution. Drosophila
melanogaster and Caenorhabditis elegans
only have one miRNA34 gene.
(B and C) Expression levels of miRNA34a (B)
and miRNA34b (C) in different mouse organs.
miRNA34c expression levels closely parallel
miRNA34b levels and are shown in
Figure S5. The mean and standard deviation
of expression levels normalized to levels of
U6 RNA are shown (31000).
(D and E) Relative expression changes of
miRNA34a (D) and miRNA34b (E) between
non-small cell lung cancers and adjacent nor-
mal tissue. The mean and standard deviation
of expression levels relative to miRNA213 ex-
pression levels are shown and are normalized
to the expression in the normal tissue of each
matched pair. Similar results were obtained
with normalization to miRNA221. Histologic
subtype and p53 mutational status (‘‘WT’’
indicates wild-type, and ‘‘MUT’’ indicates
mutated) are shown.in cancer tissues relative to normal lung (Figure 5E). No
significant correlation between p53 mutational status
and miRNA34b downregulation was observed. The ex-
pression of miRNA34a was markedly downregulated in
only 2 of 14 NSCLCs (both squamous cell carcinomas),
with modest to relatively marked overexpression of
miRNA34a in 6 of the 14 tumors (Figure 5D). Though loss
of heterozygosity (LOH) for chromosome region 11q23,
the region where miRNA34bc maps, has previously
been reported in NSCLCs, we found that 11q23 LOH
was only present in 3 out of 14 cases and was not corre-
lated with downregulation of miRNAbc (Table S4). The in-
creased methylation of a CpG island overlapping the
transcriptional unit of miRNA34bc was observed in two
of seven tumors analyzed, and only one of them demon-
strated significant downregulation of miRNA34bc (data
not shown). Given these findings, the mechanisms lead-
ing to altered levels of miRNA34 isoforms in NSCLC
are probably heterogeneous. We were interested in as-
sessing the functional consequences of expression of
miRNA34bc in NSCLC cells that had low miRNA34bc
expression and found that ectopic expression of
miRNA34bc had potent inhibitory effects on cell prolifer-
ation and/or survival in the A549 lung adenocarcinoma
cell line (Figure S6).
Discussion
Because the p53 tumor-suppressor gene is arguably the
most frequently mutated gene in human cancer, the p53protein’s function as a sequence-specific transcription
factor regulating the cellular response to diverse
stresses, such as DNA damage, hypoxia, and nutrient
deprivation, has been a subject of intense interest over
the past 15 years. Although enormous attention has
been focused on mRNAs regulated by p53, to date, little
is known about p53’s role in transcription of other types
of RNA, such as miRNAs. Using a combination of gene-
expression analyses, reporter gene assays, and ChIP
approaches, we have offered strong evidence here that
the abundance of a family of three miRNA34s is directly
regulated by p53 in cell lines and in mouse tissues. Using
a combination of array-based approaches and algo-
rithm predictions, we have identified the genes most
likely to be directly regulated by miRNA34, with cell-
cycle regulatory genes being the most prominent class
regulated by miRNA34. Following ectopic expression
of miRNA34 in cells, we observed potent effects on cell-
cycle progression and selected cell-cycle regulators.
Though apoptosis pathway genes were not predicted
to be a prominent class regulated by miRNA34, we pre-
sented robust functional evidence, obtained through the
use of antisense oligonucleotides and mouse ES cells
in which miRNA34a has been genetically inactivated,
that the BCL2 protein is regulated directly by miRNA34.
Finally, besides providing information on the tissue-
specific patterns of miRNA34 family members in mouse
tissues, we demonstrate that the expression of two
miRNA34s is dramatically reduced in a subset of
NSCLCs, particularly adenocarcinoma of the lung. Taken
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effectors of p53 tumor-suppressor function and that
their inactivation might contribute to certain cancers.
Overall, the findings we have presented here implicate
the miRNA34 family as significant downstream effectors
of p53 function in normal and cancer cells. With respect
to our observations that four of five lung adenocarci-
nomas and 6 of 14 total NSCLCs lack miRNA34bc, it is
interesting to note that p53 mutations are found in only
about 35% of lung adenocarcinomas and about 50%
of squamous cell carcinomas [30]. Perhaps the loss
of miRNA34 isoforms in some NSCLCs might serve to
mimic the consequences of p53 loss of function on cell-
cycle checkpoints and cell survival. Consistent with this
view, it is noteworthy that Welch et al. [28] recently
showed a significant downregulation of the most highly
expressed miRNA34 variant in neuronal tissue,
miRNA34a, in neuroblastoma with 1p36 allelic loss, sug-
gesting that the inactivation of miRNA34 isoforms might
play a role in multiple cancer subtypes. Further studies
of the expression and function of miRNA34 isoforms in
normal and neoplastic tissues will undoubtedly enhance
knowledge of how the miRNA34 family functions in reg-
ulating cell-cycle progression and apoptosis and per-
haps other essential functions of p53.
Experimental Procedures
Cell Culture
Wi38 human diploid fibroblasts were obtained at passage 12 (Coriell
Cell Repository [Camden, NJ]) and were cultured in modified Eagle’s
medium with Earle’s salts containing 15% fetal calf serum, penicil-
lin-streptomycin, nonessential amino acids, and 2 mM L-glutamine
(Invitrogen [Carlsbad, CA]). Experiments were performed between
passages 14 and 18. Retroviral constructs based on pSUPERIOR
PURO (Oligoengine [Seattle, WA]) carrying a shRNA targeting
p53 or a nonsilencing control [31] were packaged with the Phoenix
packaging cell line (American Type Culture Collection [ATCC] [Man-
assas, VA]), and supernatants were used in three consecutive infec-
tions in presence of 4 mg/ml polybrene (Sigma-Aldrich [St. Louis,
MO]). Polyclonal stable populations were obtained after selection
with 1 mg/ml Puromycin for 7 days. Oligonucleotides with
seven LNA nucleotides and perfect reverse complementarity to
miRNA34a, miRNA34b, and miRNA34c (in a relative molar ratio of
2:1:1) were transfected with 5 ml of Lipofectamine 2000 transfection
reagent and 50 nM of the oligonucleotides (Integrated DNA technol-
ogies [Coralville, IA]). An oligonucleotide targeting GFP with the se-
quence 50-ATGAACTTCAGGGTCAGCTTGC-30 was used as a nega-
tive control.
ES cell clone STA052 was obtained from Mutant Mouse Regional
Resource Center (MMRRC) at the University of California, Davis and
was derived from the E14Tg2a-cl4 cell line in a large-scale gene-trap
approach [32]. It was cultured on gelatin-coated tissue-culture
plates with Glasgow’s modified Eagle’s medium (Sigma) with addi-
tion of 1000 U/ml human LIF (Chemicon [Temecula, CA]), 10% fetal
calf serum (Atlanta Biologicals [Lawrenceville, GA]), penicillin-strep-
tomycin, 50 mM mercaptoethanol, nonessential amino acids, and
2 mM L-glutamine. The insertion site of the gene-trap vector was
verified and is localized in the first intron of the miRNA34a precursor
transcript. Homozygous ES cells were generated by the selection of
cells with 2 mg/ml G418 [33]. In parallel, subclones of the STA052 cell
line were isolated by the limiting of the dilution in 150 mg/ml G418.
Differentiation was induced by the plating of cells for 3 days in the
presence of 1 mM retinoic acid and in the absence of LIF. To assess
the influence of miRNA34bc re-expression on the growth of NSCLC
cell lines, we cotransfected 0.5 mg of a GFP expression plasmid
(pEGFP-C1) with 1.5 mg of pMSCV-PURO or pMSCV-miRNA34bc.
Flow cytometry was performed 4 days later, and the number of green
fluorescent cells was determined.SW480 (ATCC), HCT116 (ATCC), and HCT116 p532/2 (a generous
gift of Bert Vogelstein) were cultured in Dulbecco’s modified Eagle’s
medium in the presence of 10% fetal calf serum, penicillin-strepto-
mycin, nonessential amino acids, and 2 mM L-glutamine (Invitro-
gen). Cells were transfected with episomal doxycyclin-regulatable
expression plasmids (derived from the plasmid p-RTS1 [34]) and se-
lected in the presence of 400 ug/ml hygromycin (Invitrogen). Gene
expression was induced by 1 mg/ml doxycyclin (Sigma [St. Louis,
CA]). More than 90% of cells expressed GFP. Reporter assays to as-
sess miRNA34a and miRNA34bc promoter activity were performed
by the transfection of 0.5 mg reporter constructs, 0.5 mg of a p53
expression plasmid [22], and 0.5 mg of a CMV-b-galactosidase con-
struct in 6-well plates with Fugene 6 (Roche [Indianapolis, IA]).
Where indicated, a thymidine-kinase promoter renilla luciferase
construct was used for normalization (Promega [Madison, WI]). Re-
porter gene activity was measured with a dual-luciferase assay
system (Promega).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed essentially as de-
scribed by Weinmann et al. [35]. Cells were treated with 150 mM 5-
FU (Sigma) for 20 hr and were fixed for 10 min in 1% formaldehyde
at room temperature. Chromatin was sheared to 300–1000 bp length
with a Fisher Sonic dysmembranator eight times for 10 s each at
power level 2.5. Immunoprecipitation was performed with mouse
p53 monoclonal antibody DO1 (AB6, Calbiochem [San Diego, CA]).
Recovered chromatin was measured by quantitative PCR and
normalized to the amount in the extracts prior to immunoprecipita-
tion. Primers are available upon request.
Plasmids, DNA Sequencing, and Microarray Analysis
Details are referenced in the Supplemental Data.
Western-Blot Analysis
Protein extracts were prepared by a modified RIPA (radioimmuno-
precipitation assay) buffer with 0.5% sodium dodecyl sulfate (SDS)
in the presence of proteinase inhibitor cocktail (Complete mini,
Roche) and phosphatase inhibitors (1 mM sodium orthovanadate,
10 mM sodium fluoride). Polyacrylamide gel electrophoresis,
tank-based transfer to polyvinylidene difluoride (PVDF) membrane,
and immunodetection were performed with standard techniques.
Antibodies used were mouse BCL2 (Santa Cruz Biotechnologies
[Santa Cruz, CA]), mouse p21 (Santa Cruz Biotechnologies), rabbit
Cyclin-E2 (Cell Signaling Technology [Danvers, MA]), mouse CDK6
(Cell Signaling Technology), rabbit E2F5 (Santa-Cruz Biotechnol-
ogies), mouse b-actin (Sigma), and horseradish-peroxidase-
coupled goat antibodies against rabbit and mouse immunoglobu-
lins (Pierce [Rockford, IL]). Signals were visualized with Supersignal
West Pico chemoluminescent substrate (Pierce) by exposure to
films.
Flow Cytometry
After trypsinization, cells were washed once in phosphate-buffered
saline (PBS) and fixed in 70% ethanol overnight. Staining for DNA
content was performed with 2 mg/ml propidium iodide and 20 mg/ml
RNase A for 30 min. Analysis was performed on a FACScalibur or
LSR II flow cytometry machine (BD Biosciences [Franklin Lakes,
NJ]) with Cell Quest Pro or FACS-Aria software. Cell-cycle modeling
was performed with Modfit 3.0 software (Verity Software House
[Topsham, ME]).
For analysis of apoptotic cell populations, cells were trypsinized
and washed in cold PBS. Staining with Alexa-Fluor 647 annexin V
(Invitrogen) and propidium iodide was performed in 20 mM HEPES
(pH 7.4), 150 mM NaCl, and 2.5 mM CaCl2 for 15 min at room
temperature.
Supplemental Data
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